Lotus Bio Acquisitions & What It Means For The Co.

Lotus Bio-Technology Development Corps (OTC: $LBTD) new CEO, Christopher Hoyt, commented, “I am excited to get on board and am willing to tackle the challenges to take an unfair share in the digital health and wellness home testing market.” The company announced its Year-to-date revenues and projections for two recently acquired companies on August 2nd. The recently acquired Digital Health and Wellness Home Testing assets helped further the company in the industry. These acquisitions will provide Lotus Bio-tech with immediate access to the rapidly growing Digital Health and Wellness home testing market, joining fast-growing companies like EverlyWell and Color Health.

These two companies are already heavily involved in the health lab and home testing space, and Lotus Bio-tech believes by consolidating resources from both acquired companies, it can rapidly increase its operations, coverage, and volume. Looking forward, Lotus Bio-tech hopes to replicate the success of the two aforementioned digital health and wellness testing giants. Lotus Bio-tech is expected to generate revenues in excess of $100M in the year 2024, while continuing to launch cutting-edge health technologies which will be announced soon. The company is on schedule to produce an upwards of $100 million in revenue by 2024 as they continue to rollout cutting edge medical technology that will soon be announced.

Lotus Bio Latest YTD Earnings

The company’s total year-to-date revenues are $6.3 million, with total revenues for 2021 at a little more than $7 million. Lotus Bio-tech is committed to obtaining a winning team, and looks forward to announcing more board members in the near future. “We are not only sure of our abilities in this space, but we are honored that we will give EverlyWell and Color Health a run for their money” said CEO Christopher Hoyt.

The Acquisition of Boomerang & Focal Point

Lotus recently announced that had fully acquired the parent Focal Point Inc and its subsidiary Boomerang. Lotus Bio-tech plans on combining the two companies. Boomerang is a medical home test kit company that has expanded from heart and diabetes test to Covid-19 home testing company. This new addition to Lotus allows the company to expand its reach in the medical test industry. These acquisitions will provide Lotus Bio-tech with a foothold in the growing digital health and home testing kit market.

Boomerang Kits offers a variety of home test kits from heart and diabetes to Covid-19 which has created a new demand for home test kits since the pandemic started in 2019. The process is simple first, you order a test to be sent to your home based on some metrics such as gender, health. Upon receiving the home test kit you would have to register it online to get a unique ID with the lab system. Then, the company provided a pre-paid shipping label to return it to the lab and then once its received you will be notified of the results. The covid-19 home test kid does not need to be sent back to the lab to receive the results.

Moving Forward For Lotus Bio

Lotus Bio-Technology Development Corp. operations are organizational matters, planning of its website, and development of its business plan. Lotus Biotech Development has formed a solid team for producing and processing

Management is strategizing on branding, marketing, and sales, completing product development, and readying for the completion of production of the Lotus Biotechnology. The company has an extremely easy-to-use online interface, complete with an easy-to-follow four-step process. The company ships kits of at-home tests direct to customers, which allows customers to use supplied materials to make their own samples and send it through the mail using included expedited shipping.

Disclaimer

PennyStocks.News (PSN) is a website owned and operated by WordPress. By accessing this website or any page thereof, you agree to be bound by the Terms of Use and Privacy Policy, in effect at the time you access this website or any page thereof. The Terms of Use and Privacy Policy may be amended from time to time. Nothing on this website shall constitute an offer to sell, or a solicitation of an offer to buy or subscribe for, any securities to any person in any jurisdiction where such an offer or solicitation is against the law or to anyone to whom it is unlawful to make such offer or solicitation. PSN is not an underwriter, broker-dealer, Title III crowdfunding portal or a valuation service and does not engage in any activities requiring any such registration. Grit does not provide advice on investments or structure transactions. Offerings made under Regulation A under the U.S. Securities Act of 1933, as amended (the “Securities Act”) are available to U.S. investors who are “accredited investors” as defined by Rule 501 of Regulation D under the Securities Act well as non-accredited investors, who are subject to certain investment limitations as set forth in Regulation A under the Securities Act. In order to invest in Regulation A offerings, investors may be asked to fill out a certification and provide necessary documentation as proof of your income and/or net worth to verify that you are qualified to invest in offerings posted on this website. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities.